Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, November 13, 2023
[ Mon, Nov 13th 2023
] - WOPRAI
Sun, November 12, 2023
[ Sun, Nov 12th 2023
] - WOPRAI
Fri, November 10, 2023
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
[ Fri, Nov 10th 2023
] - WOPRAI
Etzer Darout Maintained (ACRV) at Buy with Decreased Target to $24 on, Nov 10th, 2023
Etzer Darout of BMO Capital, Maintained "Acrivon Therapeutics, Inc." (ACRV) at Buy with Decreased Target from $25 to $24 on, Nov 10th, 2023.
Etzer has made no other calls on ACRV in the last 4 months.
There are 3 other peers that have a rating on ACRV. Out of the 3 peers that are also analyzing ACRV, 0 agree with Etzer's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Etzer
- Michael Okunewitch of "Maxim Group" Initiated at Strong Buy and Held Target at $24 on, Thursday, October 5th, 2023
- Emily Bodnar of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $20 on, Wednesday, September 6th, 2023
- Soumit Roy of "JonesTrading" Initiated at Strong Buy and Held Target at $26 on, Friday, August 18th, 2023
